Clinical utilities of aromatase inhibitors in breast cancer

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Aromatase is an enzyme that converts testosterones to estrogens. Inhibition of this enzyme has been shown to have several clinical utilities in breast cancer. Currently, there are three aromatase inhibitors (AIs) in clinical use, namely anastrozole, letrozole, and exemestane. AIs have been used in various clinical settings for breast cancer, ranging from chemoprevention in breast cancer to treating breast cancer in both early stage in the adjuvant setting and metastatic disease. This article reviews mechanism of action, AI classification, and clinical utilities of AIs in various clinical settings in the context of breast cancer.

Original languageEnglish (US)
Pages (from-to)493-499
Number of pages7
JournalInternational Journal of Women's Health
Volume7
DOIs
StatePublished - May 6 2015

Fingerprint

Aromatase Inhibitors
Breast Neoplasms
exemestane
letrozole
Aromatase
Chemoprevention
Enzymes
Testosterone
Estrogens

Keywords

  • Aromatase inhibitor
  • Breast cancer
  • Endocrine therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Maternity and Midwifery

Cite this

Clinical utilities of aromatase inhibitors in breast cancer. / Chumsri, Saranya.

In: International Journal of Women's Health, Vol. 7, 06.05.2015, p. 493-499.

Research output: Contribution to journalReview article

@article{eccee749b88b43f8a913842d277ea47e,
title = "Clinical utilities of aromatase inhibitors in breast cancer",
abstract = "Aromatase is an enzyme that converts testosterones to estrogens. Inhibition of this enzyme has been shown to have several clinical utilities in breast cancer. Currently, there are three aromatase inhibitors (AIs) in clinical use, namely anastrozole, letrozole, and exemestane. AIs have been used in various clinical settings for breast cancer, ranging from chemoprevention in breast cancer to treating breast cancer in both early stage in the adjuvant setting and metastatic disease. This article reviews mechanism of action, AI classification, and clinical utilities of AIs in various clinical settings in the context of breast cancer.",
keywords = "Aromatase inhibitor, Breast cancer, Endocrine therapy",
author = "Saranya Chumsri",
year = "2015",
month = "5",
day = "6",
doi = "10.2147/IJWH.S69907",
language = "English (US)",
volume = "7",
pages = "493--499",
journal = "International Journal of Women's Health",
issn = "1179-1411",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Clinical utilities of aromatase inhibitors in breast cancer

AU - Chumsri, Saranya

PY - 2015/5/6

Y1 - 2015/5/6

N2 - Aromatase is an enzyme that converts testosterones to estrogens. Inhibition of this enzyme has been shown to have several clinical utilities in breast cancer. Currently, there are three aromatase inhibitors (AIs) in clinical use, namely anastrozole, letrozole, and exemestane. AIs have been used in various clinical settings for breast cancer, ranging from chemoprevention in breast cancer to treating breast cancer in both early stage in the adjuvant setting and metastatic disease. This article reviews mechanism of action, AI classification, and clinical utilities of AIs in various clinical settings in the context of breast cancer.

AB - Aromatase is an enzyme that converts testosterones to estrogens. Inhibition of this enzyme has been shown to have several clinical utilities in breast cancer. Currently, there are three aromatase inhibitors (AIs) in clinical use, namely anastrozole, letrozole, and exemestane. AIs have been used in various clinical settings for breast cancer, ranging from chemoprevention in breast cancer to treating breast cancer in both early stage in the adjuvant setting and metastatic disease. This article reviews mechanism of action, AI classification, and clinical utilities of AIs in various clinical settings in the context of breast cancer.

KW - Aromatase inhibitor

KW - Breast cancer

KW - Endocrine therapy

UR - http://www.scopus.com/inward/record.url?scp=84930935676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930935676&partnerID=8YFLogxK

U2 - 10.2147/IJWH.S69907

DO - 10.2147/IJWH.S69907

M3 - Review article

VL - 7

SP - 493

EP - 499

JO - International Journal of Women's Health

JF - International Journal of Women's Health

SN - 1179-1411

ER -